FACO China–Japan Expert Dialogue | Professors Jin Li, Xiaotian Zhang, and Koji Kono Discuss Precision Treatment Advances in HER2-Positive Gastric Cancer
China, Japan, and other Asian countries have some of the highest rates of gastric cancer worldwide. In China, the majority of patients are still diagnosed at an advanced stage, having already lost the opportunity for curative surgery. Effective systemic therapy is therefore essential for improving survival. In recent years, innovative drugs represented by antibody–drug conjugates (ADCs)—such as the HER2-targeted ADC trastuzumab deruxtecan (T-DXd)—have achieved major breakthroughs in pivotal clinical studies including DESTINY-Gastric04. These advances are expected to gradually transform the treatment landscape starting from later lines of therapy. Asian clinical researchers have played an important role in these studies, contributing insights that are redefining clinical practice.
Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…
Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy
On November 2, 2025, world-renowned hematology experts Professor Michael R. Bishop, Director of the Cell Therapy Center at the University of Chicago, and Professor Edmund K. Waller, the Rein Saral Distinguished Chair at Emory University, visited the Peking University Institute of Hematology for an academic exchange.
Prof. Kun Wang: A 72-Hour Pegfilgrastim Dosing Strategy Significantly Reduces Bone Pain and Optimizes Supportive Care in Breast Cancer
Editor’s Note At the ESMO 2025 Congress, Prof. Kun Wang from Guangdong Provincial People’s Hospital delivered an oral presentation reporting results from a prospective phase III trial exploring the relationship…
ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients
In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.
ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer
At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.
ESMO China Voice | Prof. Jian Zhang: SMP-656 Shows Early Promise, Offering New Hope for Patients Resistant to HER2 ADC Therapy
Editor’s Note: With its remarkable therapeutic efficacy, DS-8201 has dramatically reshaped the treatment landscape for patients with advanced breast cancer. In HER2-positive advanced breast cancer, DS-8201 has firmly established its…
Bridging the World, Shaping the Future | 2025 CRHA Conference on Frontiers in Cell Therapy and Biomedicine Opens in Xiong’an
Editor’s Note: In the golden season of autumn, leading experts gathered in the City of the Future to discuss the frontiers of cell therapy. On October 31, 2025, the 2025…
Professor Liang Aibin: Advances in Universal CAR-T Therapy | 2025 Conference on Cell Therapy and Biomedical Frontiers
Editor’s Note: Universal CAR-T cell therapy has emerged as one of the most dynamic frontiers in cellular immunotherapy. Characterized by its “off-the-shelf” availability and broad clinical potential, it has drawn…